| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―May―17 |
Development of a Deep Learning-Based Quantitative Structure-Activity Relationship Model to Identify Potential Inhibitors Against the 3C-like Protease of SARS-CoV-2 |
Madhulata Kumari, Naidu Subbarao |
| 2 |
[GO] |
2024―Apr―15 |
Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2 |
Yong Yan, Hanwen Liu, Di Wu, Zhihao Gu, Wenhao Guo, Hequan Yao, et al. (+2) Kejiang Lin, Xuanyi Li |
| 3 |
[GO] |
2023―Jul―12 |
Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors |
Vinícius Gonçalves Maltarollo, Elany Barbosa da Silva, Thales Kronenberger, Marina Mol Sena Andrade, Gabriel V de Lima Marques, Nereu J Cândido Oliveira, et al. (+28) Lucianna H Santos, Celso de Oliveira Rezende Júnior, Ana C Cassiano Martinho, Danielle Skinner, Pavla Fajtová, Thaís H M Fernandes, Eduardo da Silveira dos Santos, Poliana A Rodrigues Gazolla, Ana P Martins de Souza, Milene Lopes da Silva, Fabíola S dos Santos, Stefânia N Lavorato, Ana C Oliveira Bretas, Diogo Teixeira Carvalho, Lucas Lopardi Franco, Stephanie Luedtke, Miriam A Giardini, Antti Poso, Luiz C Dias, Larissa M Podust, Ricardo J Alves, James McKerrow, Saulo F Andrade, Róbson R Teixeira, Jair L Siqueira-Neto, Anthony O’Donoghue, Renata B de Oliveira, Rafaela S Ferreira |
| 4 |
[GO] |
2023―Mar―31 |
Truth and lies about the use of old drugs against COVID-19: have we learned the lesson? |
Carmine Iorio, Giuseppe Manfroni |
| 5 |
[GO] |
2023―Feb―03 |
The connection between PARP14 and SARS-CoV-2 |
Amanda L Tauber, Stephanie S Schweiker, Stephan M Levonis |
| 6 |
[GO] |
2022―May―10 |
Therapeutic potential of vitamin B1 derivative benfotiamine from diabetes to COVID-19 |
Kieran V Allowitz, John J Yoo, Justin R Taylor, Omar A Baloch, Kyra Harames, Kota V Ramana |
| 7 |
[GO] |
2022―Mar―22 |
Targeting mucin hypersecretion in COVID-19 therapy |
Parteek Prasher, Mousmee Sharma |
| 8 |
[GO] |
2022―Feb―27 |
Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening |
Li-chuan Zhang, Hui-lin Zhao, Jin Liu, Lei He, Ri-lei Yu, Cong-min Kang |
| 9 |
[GO] |
2021―Nov―24 |
Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening |
Abdulrahim R Hakami, Ahmed H Bakheit, Abdulrahman A Almehizia, Mohammed Y Ghazwani |
| 10 |
[GO] |
2021―Sep―02 |
COVID-19 diagnostic assays sensitivity: lessons for the upcoming wave or next pandemic |
Nikhil Shri Sahahjpal, Ashis K Mondal, Sudha Ananth, Kimya Jones, Alka Chaubey, Ravindra Kolhe |
| 11 |
[GO] |
2021―Jun―25 |
Rapid structure-based identification of potential SARS-CoV-2 main protease inhibitors |
M Elizabeth Sobhia, G Siva Kumar, Srikanth Sivangula, Ketan Ghosh, Harmanpreet Singh, Thongtinlal Haokip, Joseph Gibson |
| 12 |
[GO] |
2021―Jun―25 |
Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening |
Leonardo Bruno Federico, Guilherme Martins Silva, Lorane Izabel da Silva Hage-Melim, Suzane Quintana Gomes, Mariana Pegrucci Barcelos, Isaque Antônio Galindo Francischini, Carlos Henrique Tomich de Paula da Silva |
| 13 |
[GO] |
2021―Feb―16 |
De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence |
Navneet Bung, Sowmya R Krishnan, Gopalakrishnan Bulusu, Arijit Roy |
| 14 |
[GO] |
2021―Jan―20 |
The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19) |
Amanda L Tauber, Stephanie S Schweiker, Stephan M Levonis |
| 15 |
[GO] |
2021―Jan―08 |
Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database |
Jurica Novak, Hrvoje Rimac, Shivananda Kandagalla, Maria A Grishina, Vladimir A Potemkin |
| 16 |
[GO] |
2020―Nov―24 |
COVID-19 screening in a healthcare or community setting: complexity of saliva as a specimen for PCR-based testing |
Nikhil Shri Sahajpal, Ashis K Mondal, Allan Njau, Sudha Ananth, Salil Ghamande, Madhuri Hegde, et al. (+3) Alka Chaubey, Amyn M Rojiani, Ravindra Kolhe |
| 17 |
[GO] |
2020―Aug―13 |
Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study |
Witor Ribeiro Ferraz, Renan Augusto Gomes, Andre Luis S Novaes, Gustavo Henrique Goulart Trossini |
| 18 |
[GO] |
2020―Jul―16 |
Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics |
Sonya VanPatten, Mingzhu He, Ahmad Altiti, Kai F Cheng, Mustafa H Ghanem, Yousef Al-Abed |
| 19 |
[GO] |
2020―Jul―08 |
Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2 |
Shiyong Fan, Dian Xiao, Yanming Wang, Lianqi Liu, Xinbo Zhou, Wu Zhong |
| 20 |
[GO] |
2020―Jun―26 |
Vesicular drug-delivery systems as theranostics in COVID-19 |
Saurabh Satija, Meenu Mehta, Mousmee Sharma, Parteek Prasher, Gaurav Gupta, Dinesh K Chellappan, Kamal Dua |
| 21 |
[GO] |
2020―Jun―22 |
Tackling SARS-CoV-2: proposed targets and repurposed drugs |
Siddhi Joshi, Maithili Joshi, Mariam S Degani |
| 22 |
[GO] |
2020―Jun―19 |
Role of clinical laboratories in response to the COVID-19 pandemic |
Nikhil Shri Sahajpal, Allan Njau, Ashis K Mondal, Sudha Ananth, Alka Chaubey, Amyn Rojiani, Ravindra Kolhe |
|
